Skip to main content

CTOS 2025 Main banner

Icon Legend

This session is not in your schedule.

This session is in your schedule. Click again to remove it.

Hans-Henning Boehm, PhD

Merck Healthcare KGaA, Germany

Poster(s):

(P 42) PRECLINICAL VALIDATION OF M3554, A NOVEL ANTI-GD2 ANTIBODY-DRUG CONJUGATE, AND EPIGENETIC SENSITIZATION STRATEGIES IN SOFT TISSUE SARCOMAS